Founder And President
Co-Founding Partner and COO
Chief Financial Officer
Chief People Officer
Partner, Launch Excellence Practice Lead
Partner, Patient Services Practice Lead
Partner, Market Access Practice Lead
General Manager, SixSense Strategy Group, Medical Affairs Practice Lead
Principal, Medical Communications
Principal, Evidence and Value
Principal, Science and Strategy
Principal, Evidence and Value
Principal, Market Access
Principal, Market Access
Principal
Principal
Principal, Scientific Communications
Principal, Science and Strategy
Senior Director, Market Access
Senior Vice President, Commercialization
Vice President, Commercialization
Director, Market Access
Senior Vice President, Commercialization
Director, Patient Services
Vice President, Business Development
Executive Vice President, Business Development
Senior Vice President, Commercialization
Emily comes to us with 20+ years of reimbursement and market access experience, first working as a reimbursement consultant at Xcenda for 9 years, providing multiple pharmaceutical and biotech clients with pre- and-post commercialization strategies and tactics to help launch a variety of physician-administered drugs, biologics, and devices. Emily worked with leaders across managed markets, reimbursement, trade, marketing, and sales teams to help overcome payer access barriers, including coverage, coding, and payment needs.
Emily transitioned into the pharmaceutical industry for 10 years, where she led and managed reimbursement strategy and health policy needs at Salix Pharmaceuticals, Otsuka, and Pharming Healthcare. Emily was responsible for managing Hub, PAP, copay programs, field reimbursement teams, as well as clinical nurse educators to ensure patient access and adherence. With this experience, she was most recently able to help a few service providers directly and open her own consulting practice to enhance patient and provider experience. Emily will be bringing to us some of her existing clients, while focusing on growing our client base.
In her spare time, Emily enjoys hiking, playing disc golf, spending time with her family and dog, and traveling. Emily has recently become an Owl’s fan with her son attending Temple University.
The Centers for Medicare & Medicaid Services (CMS) just announced the first set of drugs and biologics for price negotiations to be effective 2026. Read the article to find out more.
Since CMS announced the first ten drugs selected for price negotiation on August 29th, 2023, primary manufacturers had until October 1st, 2023, to sign agreements to participate in the Price Negotiation Program. Read the article to find out more.
The IRA will make many improvements to the Medicare program overall, and many on the pharmaceutical side have been mainly focused on preparing for the Medicare Drug Price Negotiation Program. Download this paper to understand the current timelines and guidance.
Uncover how the Inflation Reduction Act revolutionizes Medicare & drug prices. Stay ahead with Herspiegel's insights. Read now.
Careers page Analyst profile
Careers page Manager profile
Careers page, Principal profile